Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial

Autor: M. Rohr, M. Roux, A. De Gea-Hominal, G. Blanchard-Rohner, P.H. Lambert, W. Wijagkanalan, Pierre-Henri Benhamou, P.L. Hervé, Benjamin Pelletier, Angela Huttner, H.T. Pham, A. Matthey, G. Gutknecht, Claire-Anne Siegrist, Lucie Mondoulet, C. Hayem, O. Chatzis, B. Lemaître

Publikováno v: Clinical microbiology and infection, Vol. 27, no. 6, p. 878-885 (2021)
Clinical Microbiology and Infection, Vol. 32, No 7 (2020) pp. 768-776

Objectives Protection induced by acellular vaccines can be short, requiring novel immunization strategies. Objectives of this study were to evaluate safety and capacity of a recombinant pertussis toxin (PTgen) -coated Viaskin® epicutaneous patch to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de3103033e958e6061f7afc3fc3f4fd1
https://hdl.handle.net/2078.1/241372